New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
12:50 EDTARNAArena rallies after partner announces broader coverage for Belviq
Arena Pharmaceuticals (ARNA) partner Eisai announced earlier that it has secured improved patient access of weight loss drug Belviq with CVS Caremark (CVS) and Aetna (AET). CVS Caremark customers have broadened the coverage of Eisai's Belviq, according to Fingertip Formulary, a database of formulary information, the company said. Fingertip Formulary reports that depending on the design of the health plan or employer benefit, eligible CVS Caremark members may have access to Belviq in either a preferred or non-preferred brand position, it added. In addition, Fingertip Formulary states that the number of insured commercial lives in the United States with coverage for Belviq now exceeds 50%. Eisai added that Aetna recently announced that it would offer Belviq as a preferred brand to eligible patients as part of its pilot program to self-insured plan sponsors. Belviq is a registered trademark of Arena Pharmaceuticals (ARNA). Shares of Arena are up 5% to $6.28 in early afternoon trading.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
11:03 EDTARNAPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use